br105

BR105 is a novel, humanized immunoglobulin G1 monoclonal antibody with a silent Fc design, specifically targeting signal regulatory protein alpha (SIRPα). It binds to major SIRPα variants and blocks the interaction between SIRPα and its ligand CD47, thereby abolishing the “don’t eat me” signal that prevents macrophages from phagocytosing tumor cells. This mechanism activates macrophages to carry out their tumor phagocytic function, achieving antitumor immunotherapy. BR105 has demonstrated broad binding activity across various SIRPα variants and does not inhibit T cell activation. Preclinical studies show it synergizes with therapeutic antibodies to promote phagocytosis of tumor cells and significantly inhibits tumor growth in xenograft models. Clinical trials have shown promising efficacy and safety profiles in lymphoid malignancies[1][3][7].

Other names

BR105 injectionBR-105 injectionBR 105 injection